Skip to main content

Advertisement

Table 2 Patient and tumor information including: tumour-type: Merkel cell carcinoma (MCC), basal cell carcinoma (BCC), squamous cell carcinoma (SCC) or normal skin (NS); sample date; disease stage; level of MCPyV large T-antigen mRNA expression: high (H), medium (M), low (L) or no expression (N); mean (SD) TrkA and TrkAIII percentage of total TrkA (TrkA + TrkAIII) RT-PCR levels; mean (SD) densitometric TrkA and TrkAIII ratios to 18S rRNA RT-PCR levels; anti-TrkA and Y490 phosphorylated TrkA (anti-pY490 TrkA) immunoreactivity in tissue samples: strong (S), medium (M), weak (W) or negative (N); patient therapy: surgery (S) and locoregional Melphalan chemotherapy (C)

From: A pilot study of alternative TrkAIII splicing in Merkel cell carcinoma: a potential oncogenic mechanism and novel therapeutic target

Patient Date of sample (m/y) Stage Large T-ag %TrkA Mean (SD) %TrkAIII Mean (SD) Mean (SD) Ratio TrkA:18S rRNA Mean (SD) Ratio TrkAIII:18S rRNA IF anti-TrkA IF anti-pY490 TrkA Therapy
MCC
 1 06–2014 (i) IV H 1.88 (4.5) 98.12 (4.5) 0.016 (0.002) 0.834 (0.03) S S S/C
09–2014 (ii) IV H 23.4 (8.4) 76.6 (8.4) 0.036 (0.007) 0.12 (0.01 M M S/C
12–2014 (iii) IV M/H 23.1 (6.5) 76.9 (6.5) 0.08 (0.001) 0.44 (0.02) S M S/C
08–2015 (iv) IV H 8.6 (5.4) 91.4 (5.4) 0.034 (0.001) 0.4 (0.01) M M S/C
 2 02–2008 (i) IV H 31.9 (4.5) 68.1 (4.5) 0.2 (0.01) 0.43 (0.02) S S S/C
02–2008 (ii) IV H 1.3 (4.2) 98.7 (4.2 0.003 (0.0001) 0.26 (0.02) S S S/C
02–2008 (iii) IV H 1.9 (6.1) 98.1 (6.1) 0.002 (0.0001) 0.2 (0.01) M S S/C
 3 08–2011 (i) IV M 0.4 (4.2) 99.6 (4.2) 0.003 (0.0002) 0.68 (0.03) S S S/C
08–2011 (ii) IV M/H 0.8 (8.4) 99.2 (8.4) 0.001 (0.0003) 0.09 (0.002) M W S/C
 4 10–2012 (i) I M/H 6.2 (8.4) 93.8 (8.4) 0.02 (0.0013) 0.75 (0.02) S S S
02–2013 (ii) IV M 12.4 (8.2) 87.6 (8.2) 0.002 (0.0001) 0.08 (0.002) M M S
 5 02–2017 IIA H 16.8 (7.9) 83.2 (7.9) 0.14 (0.005) 0.72 (0.002) S W S
 6 09–2006 IIA H 2.7 (8.4) 97.3 (8.4) 0.003 (0.0002) 0.09 (0.003) L N S
 7 01–2010 IIA L/M 28.5 (6.8) 71.5 (6.8) 0.08 (0.002) 0.19 (0.003) L M S
 8 11–2007 IIB M/H 58.5 (6.7) 41.5 (6.7) 0.2 (0.002) 0.18 (0.003) S M S
 9 01–2013 IIA H 47.4 (6.5) 52.6 (6.5) 0.19 (0.003) 0.22 (0.004) S S S
 10 01–2006 IIIB H 58.5 (6.7) 41.5 (6.7) 0.055 (0.001) 0.08 (0.003) L N S
 11 01–2019 I N 98.6 (0.2) 1.4 (0.2) 0.4 (0.002) 0.008 (0.001) L N S
BCC
 12 01–2018 I N 99.5 (0.04) 0.5 (0.04) 0.1 (0.02) 0.004 (0.0001) N N S
 13 02–2018 I N 99.8 (0.02) 0.2 (0.02) 0.04 (0.002) 0.08 (0.002) W N S
 14 01–2019 I L 99.9 (0.04) 0.1 (0.04) 0.213 (0.012) 0.02 (0.001) N N S
SCC
15 02–2019 I N 99.8 (0.02) 0.2 (0.02) 0.18 (0.002) 0.001 (0.0002) N N S
16 01–2019 I N 99.8 (0.05) 0.2 (0.05) 1.3 (0.03) 0.004 (0.0002) S N S
17 03–2019 I N 99.04 (0.05) 0.06 (0.05) 0.17 (0.02) 0.008 (0.0002) W N S
Normal Skin
NS 1    N 99.6 (0.02) 0.4 (0.02) 0.45 (0.01) 0.0001 (0.00002) S N S
NS 2    N 99.3 (0.01) 0.7 (0.01) 0.66 (0.023) 0.0001 (0.00002) S N S